Whitebox Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Whitebox Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-57,500	Closed	-$3.67K	–	755
2022 Q4	$3.67K	Hold	57,500	–	–	﹤0.01%	580
2022 Q3	$3K	Hold	57,500	–	–	﹤0.01%	830
2022 Q2	$5K	Hold	57,500	–	–	﹤0.01%	785
2022 Q1	$14K	Sell	57,500 -5,000	-8%	-$1.59K	﹤0.01%	767
2021 Q4	$41K	Buy	+62,500	New	+$43.4K	﹤0.01%	636
2021 Q2	–	Sell	-62,500	Closed	-$43.4K	–	632
2021 Q1	$38K	Buy	+62,500	New	+$44.1K	﹤0.01%	338

Whitebox Advisors's BIOTW Position: Q1 2023 in Review

Whitebox Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 57,500 shares — an estimated $3.67K sold.

Whitebox Advisors first reported a position in BIOTW in Q1 2021 and held it in 6 quarters. The position peaked at $41K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Whitebox Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Whitebox Advisors sold 57,500 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $3.67K.
Whitebox Advisors first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 6 quarters.
Whitebox Advisors's Biotech Acquisition Company Warrant position peaked at $41K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Whitebox Advisors's 13F filing for Q1 2023, filed 15 May 2023.